Scientific Founder and Special Advisor
Pathology and Laboratory Medicine
REGENXBIO Inc
United States of America
Dr. James M. Wilson, also known as Jim, M.D., Ph.D. serves as Chairman of Scientific Advisory Council at Dimension Therapeutics, Inc. Mr. Wilson is the Scientific Founder of Regenxbio Inc. and has been its Special Advisor since April 7, 2017. Mr. Wilson served as the Chief Scientific Advisor at Regenxbio Inc. since September 2014 until April 7, 2017. He served as Chairman of Scientific and Technical Advisory Board at Dimension Therapeutics, Inc. since October 31, 2013. Mr. Wilson is the Professor and Director of the Gene Therapy Program in the Department of Pathology and Laboratory Medicine and Professor in the Department of Internal Medicine at the University of Pennsylvania. Nineteen years ago, he moved his laboratory and family to Philadelphia and joined the faculty of the University of Pennsylvania. His research interests are gene therapy, genetic diseases, virology and vaccines for infectious diseases. A primary focus of his research is the study of cystic fibrosis and development of new treatments based on gene therapy. He has published over 497 papers and chapters in books and is on the editorial board of 12 scientific journals, serving as Editor-in-Chief of Human Gene Therapy. He is a Scientific Founder of REGENX BioSciences and is a Consultant to REGENX Holdings, a Founding Member of REGENX BioSciences. He served as the President of the American Society of Gene Therapy and served as Trustee of Albion College and the Franklin Institute. He serves as a Director of Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. Dr. Wilson received his Undergraduate Degree from Albion College with a B.S. in Chemistry and his M.D. and Ph.D. from the University of Michigan. Following a residency in Internal Medicine at the Harvard affiliated Massachusetts General Hospital and a postdoctoral fellowship at MIT, he returned to the University of Michigan, where he took his first faculty position beginning his studies in gene therapy.